Nifedipine activates PPARγ and exerts antioxidative action through Cu/ZnSOD independent of blood-pressure lowering in SHRSP

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 8, 2010, Pages 785-795

  Hashimoto, Ryo ^a   Umemoto, Seiji ^b   Guo, Fengling ^a   Umeji, Kyoko ^a   Itoh, Shinichi ^a   Kishi, Hiroko ^a   Kobayashi, Sei ^a   Matsuzaki, Masunori ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Calcium channel blocker; Hypertension; Peroxisome proliferator activated receptor; Superoxide dismutase; Vascular remodeling

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADIPONECTIN; COPPER ZINC SUPEROXIDE DISMUTASE; NIFEDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; CALCIUM CHANNEL BLOCKING AGENT; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; FIBROSIS; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; HYPERTENSION; MALE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; WISTAR KYOTO RAT; ANIMAL; AORTA; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOBLOTTING; MESENTERIC ARTERY; METABOLISM; PATHOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANILIDES; ANIMALS; AORTA; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HYPERTENSION; IMMUNOBLOTTING; MALE; MESENTERIC ARTERIES; MUSCLE, SMOOTH, VASCULAR; NIFEDIPINE; OXIDATIVE STRESS; PPAR GAMMA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; STROKE; SUPEROXIDE DISMUTASE; SUPEROXIDES;

EID: 77957127403     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.4556     Document Type: Article

References (43)

1. Kobayashi S, Inoue N, Azumi H, Seno T, Hirata K, Kawashima S, Hayashi Y, Itoh H, Yokozaki H, Yokoyama M: Expressional changes of the vascular antioxidant system in atherosclerotic coronary arteries. J Atheroscler Thromb, 2002; 9: 184-190
2. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res, 2000; 86: 494-501
3. Kondo T, Hirose M, Kageyama K: Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb, 2009; 16: 532-538
4. Faraci FM, Didion SP: Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol, 2004; 24: 1367-1373
5. Marx N, Duez H, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res, 2004; 94: 1168-1178
6. Touyz RM, Schiffrin EL: Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol, 2006; 45: 19-28
7. Nohara A, Kobayashi J, Mabuchi H: Retinoid X receptor heterodimer variants and cardiovascular risk factors. J Atheroscler Thromb, 2009; 16: 303-318
8. Schiffrin EL: More evidence of cardiorenal protective effects of peroxisome proliferator-activated receptor activation. Hypertension, 2005; 46: 267-268
9. Chang MS, Yoo HY, Rho HM: Transcriptional regulation and environmental induction of gene encoding copperand zinc-containing superoxide dismutase. Methods Enzymol, 2002; 349: 293-305
10. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 2001; 50: 2094-2099
11. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism, 2001; 50: 3-11
12. Croom KF, Wellington K: Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris. Drugs, 2006; 66: 497-528
13. Yamagishi S, Nakamura K, Takenaka K, Matsui T, Inoue H: Pleiotropic effects of nifedipine on atherosclerosis. Curr Pharm Des, 2006; 12: 1543-1547
14. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet, 2004; 364: 849-857
15. Nayler WG: Review of preclinical data of calcium channel blockers and atherosclerosis. J Cardiovasc Pharmacol, 1999; 33 Suppl 2: S7-S11
16. Fukuo K, Yang J, Yasuda O, Mogi M, Suhara T, Sato N, Suzuki T, Morimoto S, Ogihara T: Nifedipine indirectly upregulates superoxide dismutase expression in endothelial cells via vascular smooth muscle cell-dependent pathways. Circulation, 2002; 106: 356-361
17. Kubo M, Umemoto S, Fujii K, Itoh S, Tanaka M, Kawahara S, Matsuzaki M: Effects of angiotensin II type 1 receptor antagonist on smooth muscle cell phenotype in intramyocardial arteries from spontaneously hypertensive rats. Hypertens Res, 2004; 27: 685-693
18. Shibata R, Sato K, Kumada M, Izumiya Y, Sonoda M, Kihara S, Ouchi N, Walsh K: Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment. Cardiovasc Res, 2007; 74: 471-479
19. Skurk C, Wittchen F, Suckau L, Witt H, Noutsias M, Fechner H, Schultheiss HP, Poller W: Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J, 2008; 29: 1168-1180
20. Kawahara S, Umemoto S, Tanaka M, Umeji K, Matsuda S, Kubo M, Matsuzaki M: Up-regulation of Akt and eNOS induces vascular smooth muscle cell differentiation in hypertension in vivo. J Cardiovasc Pharmacol, 2005; 45: 367-374
21. Itoh S, Umemoto S, Hiromoto M, Toma Y, Tomochika Y, Aoyagi S, Tanaka M, Fujii T, Matsuzaki M: Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. Circulation, 2002; 105: 2288-2295
22. Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev N, Alexander RW: Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation, 2005; 111: 2347-2355
23. Umeji K, Umemoto S, Itoh S, Tanaka M, Kawahara S, Fukai T, Matsuzaki M: Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol Heart Circ Physiol, 2006; 291: H2522-H2532
24. Nebot C, Moutet M, Huet P, Xu JZ, Yadan JC, Chaudiere J: Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of a tetracyclic catechol. Anal Biochem, 1993; 214: 442-451
25. Umemoto S, Tanaka M, Kawahara S, Kubo M, Umeji K, Hashimoto R, Matsuzaki M: Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res, 2004; 27: 877-885
26. Zhao R, Shen GX: Functional modulation of antioxidant enzymes in vascular endothelial cells by glycated LDL. Atherosclerosis, 2005; 179: 277-284
27. Onaka U, Fujii K, Abe I, Fujishima M: Antihypertensive treatment improves endothelium-dependent hyperpolarization in the mesenteric artery of spontaneously hypertensive rats. Circulation, 1998; 98: 175-182
28. Umemoto S, Kawahara S, Hashimoto R, Umeji K, Matsuda S, Tanaka M, Kubo M, Matsuzaki M: Different effects of amlodipine and enalapril on the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase pathway for induction of vascular smooth muscle cell differentiation in vivo. Hypertens Res, 2006; 29: 179-186
29. Fukuo K, Yang J, Suzuki T, Kaimoto T, Takemura Y, Yasuda O, Suhara T, Sato N, Ogihara T: Nifedipine upregulates manganese superoxide dismutase expression in vascular smooth muscle cells via endothelial cell-dependent pathways. Hypertens Res, 2003; 26: 503-508
30. Fukai T, Folz RJ, Landmesser U, Harrison DG: Extra-cellular superoxide dismutase and cardiovascular disease. Cardiovasc Res, 2002; 55: 239-249
31. Marklund SL: Extracellular superoxide dismutase and other superoxide dismutase isoenzymes in tissues from nine mammalian species. Biochem J, 1984; 222: 649-655
32. Leopold JA, Loscalzo J: Oxidative enzymopathies and vascular disease. Arterioscler Thromb Vasc Biol, 2005; 25: 1332-1340
33. Wassmann S, Wassmann K, Nickenig G: Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension, 2004; 44: 381-386
34. Liochev SI, Fridovich I: The effects of superoxide dismutase on H2O2 formation. Free Radic Biol Med, 2007; 42: 1465-1469
35. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A: The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol, 2006; 26: 2731-2737
36. Chen X, Touyz RM, Park JB, Schiffrin EL: Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension, 2001; 38: 606-611
37. Fujii K, Umemoto S, Fujii A, Yonezawa T, Sakumura T, Matsuzaki M: Angiotensin II type 1 receptor antagonist downregulates nonmuscle myosin heavy chains in spontaneously hypertensive rat aorta. Hypertension, 1999; 33: 975-980
38. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M: Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol, 2000; 20: 2175-2183
39. Cai H, Griendling KK, Harrison DG: The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci, 2003; 24: 471-478
40. Atkins KB, Northcott CA, Watts SW, and Brosius FC: Effects of PPAR-γ ligands on vascular smooth muscle marker expression in hypertensive and normal arteries. Am J Physiol Heart Circ Physiol, 2005; 288: H235-H243
41. Koh KK, Oh PC, Quon MJ: Does reversal of oxidative stress and inflammation provide vascular protection? Cardiovasc Res, 2009; 81: 649-659
42. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM: Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol, 2003; 23: 52-57
43. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM: Peroxisome proliferator-activated receptor γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor γ -dependent mechanisms. Arterioscler Thromb Vasc Biol, 2005; 25: 1810-1816